Westborough, MA, May 18, 2012 --(PR.com
)-- Ameridose, LLC, the leading nationwide provider of sterile admixing services to hospital pharmacies, is delighted to be a silver sponsor for the 2nd annual USP <797> Compliance Study. The 2012 study will run from May 1 – June 30, collecting survey data from facilities engaged in sterile compounding across the United States. As the largest and most comprehensive study of <797> compliance, the study effectively raises awareness of <797> standards and spotlights areas of non-compliance. In addition, study participants receive a confidential, complimentary gap analysis based on their survey entries. The gap analysis and accompanying action plan are designed to help remove some of the uncertainty that can occur when formulating an approach towards USP <797> compliance.
“Ameridose is dedicated to being a leader in sterile compounding practices,” affirmed Sophia Pasedis, PharmD and Vice President of Regulatory Affairs and Compliance for Ameridose. “The USP <797> gap analysis tool offers pharmacists a quick and convenient way to understand their compliance situation. We are truly excited to support this study and, in so doing, to help our clients.”
Facilities that conduct sterile compounding are invited to participate in the study from May 1 to June 30, 2012 at www.797study.com
using survey code B797F.
The 2012 USP <797> Compliance Study is overseen by CriticalPoint and Study Directors, Eric Kastango and Kate Douglass. Study results and analysis will be published in Pharmacy Purchasing & Products in October of 2012.
About Ameridose, LLC
) is the leading provider of high quality sterile admixed and repackaged preparations and oral repackaging services to hospital pharmacies nationwide. Ameridose, an FDA registered manufacturer, exceeds USP <797> standards and meets cGMP requirements. Committed to delivering the finest outsourcing services in the industry, Ameridose considers quality, exceptional customer service, and value to be central elements of its corporate mission.